FDA Priority Review Voucher Programs: Incentive for Industry to Develop Novel Treatments
Extension of the Sunset Clause provides additional opportunity for the FDA to award vouchers and for transference of vouchers from recipients to other sponsors.
Risk-Bearing ACOs Growing in Popularity Under Medicare Programs
On January 18, 2017, the Centers for Medicare & Medicaid Services (CMS) announced the new Accountable Care Organization (ACO) participants in the Medicare Shared Savings Program (MSSP) for 2017.
Avalere’s Take on the ACA Market Stabilization Rule
Today, the Trump administration released a proposed rule for market stabilization of the Affordable Care Act (ACA).
Capped Funding in Medicaid Could Significantly Reduce Federal Spending
Analysis shows Medicaid block grants and per capita caps could result in state budget gaps.
Initial Analysis of ICER’s Value Framework Update
Today, the Institute for Clinical and Economic Review (ICER) released an updated version of its Value Assessment Framework.
Impact of Medicare Advantage Data Submission System on Risk Scores
Avalere analyzed data from eight Medicare Advantage Organizations (MAOs) representing 1.1 million beneficiaries in more than 30 unique plans operating across the country to understand the impact of shifting the determination of plan risk scores from the Risk Adjustment Processing System (RAPS) to the new Encounter Data System (EDS).
Advancing Oncology Care Quality in the Era of Immuno-Oncology and Other Evolving Treatments
In June 2016, Avalere in collaboration with the American Society of Clinical Oncology, Cancer Support Community, Community Oncology Alliance, and Patient Advocate Foundation, and with support from Bristol-Myers Squibb, brought together a variety of healthcare stakeholders in a national Dialogue to discuss challenges and opportunities surrounding the advancement of quality in cancer care.
Avalere to Support Boehringer Ingelheim in Outcomes-Based Contracting
Avalere will empower expanded insight and improvement in outcomes for value-based diabetes medications, using Inovalon’s data resources and advanced value-based care platforms.
Promoting Shared Decision Making Around Costs to Improve Value
Avalere and the Robert Wood Johnson Foundation Launch Eight Grants to Improve Cost-of-Care Conversations Between Patients and Clinicians.
Consumer Costs Continue to Increase in 2017 Exchanges
Plans sold in exchange markets in 2017 feature higher premiums, growing consumer out-of-pocket costs, and more restricted access to providers and hospitals than in previous years, according to a new analysis from Avalere.
2017 Healthcare Industry Outlook
Avalere experts discuss the top priorities to focus on as you navigate the new landscape.
Avalere Releases Healthcare Industry Trends Report for 2017
This year will be the start of major environmental changes for the healthcare industry following a shift in the balance of power in Washington, DC, and the states.
Navigating Bundled Payment Models in 2017
Fred Bentley fills you in on the core components of the EPM final bundled payment rule and the future of bundled payment models.
Christie Teigland, PhD, Appointed to PQA Panel
Avalere Vice President, Christie Teigland, PhD, was recently appointed to the Pharmacy Quality Alliance’s (PQA) Quality Metrics Expert Panel (QMEP) for a three-year term effective January 1, 2017.
Avalere Analysis on Final EPM Bundle Rule
Today, the Centers for Medicare & Medicaid Services took another step in shifting Medicare to a value-based payment model that rewards hospitals for delivering better care at a lower cost.
Avalere 2017 Healthcare Industry Outlook
2017 will be the start of major environmental changes for the healthcare industry following a shift in the balance of power in Washington and the States. Listen to moderator Caroline Pearson set the stage for our 2017 Healthcare Industry Outlook.
E2 – Highlights of FDA and NIH in 21st Century Cures
The final signing of the 21st Century Cures Act is the culmination of 3 years of efforts by lawmakers in the House and Senate to expedite developing and making available new treatment options. In the final episode in our series, Jay Jackson discusses what changes are on the horizon for products under The Cures Act.
E1 – How 21st Century Cures May Impact Health Plans in 2017
The final signing of the 21st Century Cures Act is the culmination of three years of efforts by lawmakers in the House and Senate to expedite developing and making available new treatment options. Listen to Cara Kelly break down the impacts in episode 1 of our series on 21st Cures.
Overview of Appropriate Use Criteria for Treating Knee Osteoarthritis
Earlier this year, Avalere led a work group of rheumatology, orthopedic surgery, psychiatry, sports medicine, and primary care clinicians to develop appropriate use criteria for the use of hyaluronic acid (HA) in the treatment of knee osteoarthritis (OA).
What You Need to Know About Today’s Cures Vote
Today, the House will vote on the updated version of the 21st Century Cures Act, H.R.34.